NBQX (Synonyms: FG9202)

Name: NBQX
Brand: MedChemExpress
SKU: HY-15068
Rating: 5.0 (20 reviews)

Cat. No.: HY-15068 Purity: 99.82%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity.

For research use only. We do not sell to patients.

CAS No. : 118876-58-7

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 20 publication(s) in Google Scholar

Other Forms of NBQX:

NBQX disodium In-stock
NBQX (Standard) Get quote

20 Publications Citing Use of MCE NBQX

Cell Imaging/Staining

Histological Imaging/Staining

Flow Cytometry

ELISA

: NBQX purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Apr:139:156457.; Representative images of FJB-positive neurons, marking degenerating neurons in the CA1, CA3, and DG regions post-TBI. The results showed that, compared with the TBI‑vehicle group, the NBQX (30 mg/kg) treatment group exhibited a significant reduction in neuronal death in the CA1, CA3, and DG regions of the rat hippocampus.

: NBQX purchased from MedChemExpress. Usage Cited in: Nature. 2024 Jul;631(8022):826-834. [Abstract]; Representative images showing the calcein-PI staining of cultured neurons from Asic1a^+/+ and Asic1a^-/- mice with different treatments. GluR-B: glutamate receptor blockers consisted of 50 μM D-AP5, 10 μM NBQX and 10 μM LY341495.

: NBQX purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 May 30:133:112080. [Abstract]; NBQX (1 mg/kg/d; i.p.; once daily for 4 weeks). UNEL showed that activation of AMPAR increased cardiomyocyte apoptosis in vitro, but incubation with a NF-κB-specific inhibitor BAY 11-7082 reversed this effect.

: NBQX purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 May 30:133:112080. [Abstract]; NBQX (NB, 1 mg/kg/d; i.p.; once daily for 4 weeks). Apoptosis measurement by flow cytometry shows that activation of AMPAR increased apoptosis, but this effect was reversed by BAY 11-7082.

: NBQX purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 May 30:133:112080. [Abstract]; NBQX (NB, 30 μM; added to the medium 6 h before hypoxia stimulation). ELISA method was employed to evaluate TNF-α, IL-1β, IL-6 and IL-10 levels in the culture medium of each group(n = 6). Inhibition of AMPA receptor decreased pro-inflammatory factor production and increased anti-inflammatory factor production. *:p < 0.05;**:p < 0.01;***:p < 0.005; ****:p < 0.001.

: NBQX purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 May 11;13(9):2946-2961. [Abstract]; NBQX (10 nmol/mL, 1 µl /side, via microinjection into the mPFC) and D-AP5 effectively reduce the express of CaMKIIα, pCREB/CREB, BDNF, and TrkB in mPFC, while activation of HPC-mPFC prevents the decrease (* LPS+CNO versus LPS, # LPS+NBQX/D-AP5+CNO versus LPS+CNO). Data were presented as mean ± SEM. n=5/group. * p < 0.05, ** p < 0.01, # p<0.05, ## p<0.01.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All iGluR Isoform Specific Products:

View All Isoforms

AMPA Receptor NMDA Receptor Kainate Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity^[1].

IC₅₀ & Target

AMPA receptor^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	1.1 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA4 Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA4	[PMID: 16610801]
HEK293	IC₅₀	1.9 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA3 Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA3	[PMID: 16610801]
HEK293	IC₅₀	135 μM Compound: 4, NBQX	Antagonist activity at human recombinant GLUK6/GLUK2 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay Antagonist activity at human recombinant GLUK6/GLUK2 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay	[PMID: 17348638]
HEK293	IC₅₀	135 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK6/GLUK2 Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK6/GLUK2	[PMID: 16610801]
HEK293	IC₅₀	2.5 μM Compound: 4, NBQX	Antagonist activity at human recombinant GLUA2-AMPA receptor expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay Antagonist activity at human recombinant GLUA2-AMPA receptor expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay	[PMID: 17348638]
HEK293	IC₅₀	2.5 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA2 Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA2	[PMID: 16610801]
HEK293	IC₅₀	28 μM Compound: 4, NBQX	Antagonist activity at human recombinant GLUK5/GLUK6 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay Antagonist activity at human recombinant GLUK5/GLUK6 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay	[PMID: 17348638]
HEK293	IC₅₀	28 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5/GLUK6 by FLIPR assay Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5/GLUK6 by FLIPR assay	[PMID: 16610801]
HEK293	IC₅₀	29 μM Compound: 4, NBQX	Antagonist activity at human recombinant GLUK6 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay Antagonist activity at human recombinant GLUK6 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay	[PMID: 17348638]
HEK293	IC₅₀	29 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK6 Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK6	[PMID: 16610801]
HEK293	IC₅₀	37 μM Compound: 4, NBQX	Antagonist activity at human recombinant GLUK5 receptor expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay Antagonist activity at human recombinant GLUK5 receptor expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay	[PMID: 17348638]
HEK293	IC₅₀	37 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5 by FLIPR assay Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5 by FLIPR assay	[PMID: 16610801]
HEK293	IC₅₀	44 μM Compound: NBQX, 47	Displacement of [3H]kainate from human GLUK7 receptor expressed in HEK293 cells Displacement of [3H]kainate from human GLUK7 receptor expressed in HEK293 cells	[PMID: 16302825]
HEK293	IC₅₀	50 μM Compound: 4, NBQX	Antagonist activity at human recombinant GLUK5/GLUK2 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay Antagonist activity at human recombinant GLUK5/GLUK2 expressed in HEK293 cells assessed as inhibition of glutamate-stimulated calcium influx by FLIPR assay	[PMID: 17348638]
HEK293	IC₅₀	50 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5/GLUK2 by FLIPR assay Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUK5/GLUK2 by FLIPR assay	[PMID: 16610801]
HEK293	IC₅₀	6 μM Compound: 50,NBQX	Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA1 Inhibition of glutamate-induced calcium influx in HEK293 cells expressing human GLUA1	[PMID: 16610801]
HEK293	IC₅₀	74 μM Compound: NBQX	Antagonist activity at human recombinant GluR6 expressed in HEK cells coexpressing aequorine assessed as inhibition of glutamate-induced Ca2+ influx at 10 uM by luminescence reporter assay Antagonist activity at human recombinant GluR6 expressed in HEK cells coexpressing aequorine assessed as inhibition of glutamate-induced Ca2+ influx at 10 uM by luminescence reporter assay	[PMID: 19819046]
Neuron	IC₅₀	11.9 μM Compound: NBQX	Inhibition of kainate-induced C57BL/6N mouse hippocampal neurons excitotoxicity after 48 hrs by MTT assay Inhibition of kainate-induced C57BL/6N mouse hippocampal neurons excitotoxicity after 48 hrs by MTT assay	[PMID: 18083036]
Oocyte	IC₅₀	0.09 μM Compound: NBQX	Antagonistic activity against rat ionotropic glutamate receptor ionotropic kainate in xenopus oocytes Antagonistic activity against rat ionotropic glutamate receptor ionotropic kainate in xenopus oocytes	[PMID: 8568808]
Oocyte	IC₅₀	255 μM Compound: NBQX	Antagonistic activity against N-methyl-D-aspartate glutamate receptor 1 in Xenopus oocytes Antagonistic activity against N-methyl-D-aspartate glutamate receptor 1 in Xenopus oocytes	[PMID: 8568808]
Oocyte	IC₅₀	31 nM Compound: NBQX	Inhibitory activity against generation of currents by 50 uM kainate in Xenopus oocytes injected with rat brain mRNA Inhibitory activity against generation of currents by 50 uM kainate in Xenopus oocytes injected with rat brain mRNA	[PMID: 10843235]
Oocyte	IC₅₀	31 nM Compound: NBQX	Antagonistic activity against Ionotropic glutamate receptor AMPA using kainate-evoked current in Xenopus oocytes injected with rat brain mRNA Antagonistic activity against Ionotropic glutamate receptor AMPA using kainate-evoked current in Xenopus oocytes injected with rat brain mRNA	[PMID: 11133083]

In Vitro

NBQX (FG9202) has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NBQX (FG9202; 20 mg/kg, i.p.; for 3 days) decreases seizures induced by PTZ^[2].
NBQX is neuroprotective in a focal ischaemia model in the rat when given as an i.v. bolus dose of 30 mg/kg at the time of MCA occlusion and again at 1 h post occlusion^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats that weighed 220-240 g with pentylenetetrazole (PTZ)^[2]
Dosage:	20 mg/kg
Administration:	IP; for 3 days
Result:	Effectively reversed the behavioral abnormality of epileptic seizures of chronic PTZ administration (50mg/kg; i.p.; for 28 days) in rats.

Molecular Weight

336.28

Formula

C₁₂H₈N₄O₆S

CAS No.

118876-58-7

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(N1)C(NC2=C1C3=C(C([N+]([O-])=O)=C2)C(S(N)(=O)=O)=CC=C3)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 75 mg/mL (223.03 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

1 M NaOH : 1 mg/mL (2.97 mM; ultrasonic and warming and heat to 60°C)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9737 mL	14.8686 mL	29.7371 mL
5 mM	0.5947 mL	2.9737 mL	5.9474 mL
10 mM	0.2974 mL	1.4869 mL	2.9737 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.82%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (253 KB) HNMR (269 KB) RP-HPLC (246 KB) LCMS (86 KB)

Handling Instructions (2659 KB)

References

[1]. Fukushima K, et al. Characterization of Human Hippocampal Neural Stem/Progenitor Cells and Their Application to Physiologically Relevant Assays for Multiple Ionotropic Glutamate Receptors. J Biomol Screen. 2014 Sep; 19(8):1174-84. [Content Brief]

[2]. Wen Chen, et al. AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets. PLoS One. 2016 Nov 23;11(11):e0166672. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

1 M NaOH / DMSO	1 mM	2.9737 mL	14.8686 mL	29.7371 mL	74.3428 mL
DMSO	5 mM	0.5947 mL	2.9737 mL	5.9474 mL	14.8686 mL
	10 mM	0.2974 mL	1.4869 mL	2.9737 mL	7.4343 mL
	15 mM	0.1982 mL	0.9912 mL	1.9825 mL	4.9562 mL
	20 mM	0.1487 mL	0.7434 mL	1.4869 mL	3.7171 mL
	25 mM	0.1189 mL	0.5947 mL	1.1895 mL	2.9737 mL
	30 mM	0.0991 mL	0.4956 mL	0.9912 mL	2.4781 mL
	40 mM	0.0743 mL	0.3717 mL	0.7434 mL	1.8586 mL
	50 mM	0.0595 mL	0.2974 mL	0.5947 mL	1.4869 mL
	60 mM	0.0496 mL	0.2478 mL	0.4956 mL	1.2390 mL
	80 mM	0.0372 mL	0.1859 mL	0.3717 mL	0.9293 mL
	100 mM	0.0297 mL	0.1487 mL	0.2974 mL	0.7434 mL

NBQX Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NBQX118876-58-7FG9202FG 9202FG-9202iGluRIonotropic glutamate receptorsAMPneuroprotectiveischaemiaNMDAInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

NBQX (Synonyms: FG9202)

Customer Review

Other Forms of NBQX:

NBQX Related Antibodies

20 Publications Citing Use of MCE NBQX

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All iGluR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

NBQX Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

NBQX Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report